Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Clinical trial NCT06620302 · RECRUITING

Trial details

NCT number: NCT06620302
Sponsor: Children's Oncology Group
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Childhood Fibrolamellar Carcinoma Recurrent Childhood Fibrolamellar Carcinoma Recurrent Childhood Malignant Solid Neoplasm Recurrent Fibrolamellar Carcinoma Recurrent Malignant Solid Neoplasm Refractory Childhood Fibrolamellar Carcinoma Refractory Childhood Malignant Solid Neoplasm Refractory Fibrolamellar Carcinoma Refractory Malignant Solid Neoplasm

Start date: 2025-06-12
Primary completion: 2031-12-30
Enrollment: 81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.